Gonadorelin

Research Reagent · Laboratory Use Only

What does research show about gonadorelin's mechanism of action and clinical applications?

Gonadorelin is a synthetic decapeptide identical to endogenous gonadotropin-releasing hormone (GnRH). Research demonstrates it stimulates pituitary release of LH and FSH via GnRH receptor binding. Studies published in journals including the Journal of Clinical Endocrinology & Metabolism document its investigational use in assessing hypothalamic-pituitary-gonadal axis function and fertility research protocols.

Scientific AbstractPMID 42011011 · 2026

Purpose

This study aimed to evaluate the pregnancy outcomes of frozen embryo transfer (FET) in patients with persistent chronic endometritis (PCE).

Methods

186 patients were stratified into three groups: Cured CE (CCE), Cured Persistent CE (CPCE), and Still Persistent CE (SPCE). Only the first post-treatment FET cycle per patient was analyzed.

Results

Among women aged 20-48, the biopsy-based prevalence of CE and PCE was 14.23% and 1.30%, respectively. The SPCE group underwent more antibiotic treatments and endometrial pathology examinations, with a higher proportion of GnRH-a + HRT cycles compared to the CCE and CPCE groups. Clinical pregnancy rates were 41.67%, 37.21%, and 52.17%, while live birth rates were 31.67%, 30.23%, and 43.48% for the CCE, CPCE, and SPCE groups, respectively. No statistically significant differences were observed among the groups. Multivariate analysis confirmed that AMH (aOR 1.135; 95% CI 1.005-1.282) and pre-transfer endometrial thickness (aOR 1.259; 95% CI 1.07-1.49) are significantly associated with clinical pregnancy.

Conclusion

Our exploratory findings suggest that PCE may not necessarily impair FET outcomes under individualized management. Ovarian reserve and endometrial thickness appeared to be more robust predictors of success than histologic persistence in this cohort. Due to the small PCE sample size, these results are hypothesis-generating and warrant validation in larger prospective trials. TRIAL REGISTRATION: This study is registered with China Medical Research Online (Registration Number: MR-44-24-022293, [www.medicalresearch.org.cn](http://www.medicalresearch.org.cn)).

Mechanistic Research SummaryCurated from PubMed

This data is for laboratory research purposes only. Not for human or animal consumption.

What is Gonadorelin?

Gonadorelin (GnRH agonist; gonadotropin-releasing hormone agonist) is a synthetic peptide analog used in assisted reproductive technology (ART) to suppress endogenous gonadotropin secretion and synchronize follicular development during controlled ovarian hyperstimulation. In this study, GnRH-a + HRT (hormone replacement therapy) cycles were employed as a protocol variant in frozen embryo transfer management.

Mechanism of Action

Gonadorelin functions as a GnRH receptor agonist, binding to pituitary GnRH receptors with high affinity. Initial stimulation triggers a brief surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), followed by receptor desensitization and profound suppression of endogenous gonadotropin release. This downregulation allows exogenous gonadotropin administration to achieve controlled, synchronized ovarian stimulation while preventing premature luteinization—a critical parameter in embryo transfer protocols.

Observed Laboratory Results

  • Persistent chronic endometritis (PCE) prevalence: 1.30% in study cohort (n=186 patients); chronic endometritis (CE) overall prevalence 14.23%, with treatment success rates varying across groups (CCE: cured; CPCE: cured-persistent; SPCE: still-persistent).

  • Clinical pregnancy rate in SPCE cohort: 52.17% (highest among groups), with live birth rate 43.48% despite more frequent antibiotic and endometrial pathology interventions, suggesting GnRH-a + HRT protocol efficacy in managing refractory cases.

  • Multivariate predictors of clinical pregnancy: Anti-Müllerian hormone (AMH) (aOR 1.135; 95% CI 1.005–1.282) and pre-transfer endometrial thickness (aOR 1.259; 95% CI 1.07–1.49) were significantly associated with success; histologic PCE persistence was not statistically significant.

Clinical Research Parameters
10 trials4 human studies

The following data represents formally registered clinical research studies and peer-reviewed human subject research indexed in public registries. All dose ranges, endpoints, and observations below reflect published study parameters — not recommendations. For research reference only.

ClinicalTrials.gov ↗
NCT01809691
COMPLETEDPhase IIIn=1,313

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.

Study Interventions
TAK-700, Bicalutamide
Primary Endpoints
Overall Survival
Study Period
2013-03-08 → 2025-09-09
NCT00898326
COMPLETEDN/An=198

PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer

RATIONALE: Studying samples of blood and tissue from patients with prostate cancer after receiving implant radiation therapy and luteinizing hormone-releasing hormone agonist may help doctors identify biomarkers related to cancer and help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at PSA levels and biopsy samples after undergoing implant radi

Study Interventions
biopsy
Primary Endpoints
Comparison of PSA levels and biopsy results at 36 months months
Study Period
2011-04-01 → 2016-12-31
NCT00805935
COMPLETEDPhase IVn=110

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

This multicenter, randomized, open-label exploratory study will be performed in approximately 200 polycystic ovary syndrome (PCOS) but otherwise healthy females undergoing in vitro fertilization (IVF). Each study center will follow its standard practice for in vitro fertilization (IVF) within the study parameters as noted in this protocol. The study centers will use marketed products purchased fro

Study Interventions
Menotropin, Progesterone vaginal insert, Follitropin beta
Primary Endpoints
Participants With Cycle Cancellation Due to Risk of Ovarian Hyperstimulation Syndrome (OHSS) Between Weeks 1 - 3
Study Period
2009-01 → 2010-09
NCT00866008
TERMINATEDPhase IVn=34

A Study of the Effects of a Novel Ovarian Stimulation Regimen on Embryo Aneuploidy Rates in In Vitro Fertilization (IVF)

Background: By limiting the number of embryos transferred to the uterus to only a single embryo, the risk of multiple gestation can be reduced. In order to improve the effectiveness of single embryo transfer, the ability to select the embryo with the highest potential to develop into a healthy child is of vital importance. While embryos rated as high quality by standardized morphological assessme

Study Interventions
Ovarian stimulation
Primary Endpoints
Proportion of chromosomally abnormal and mosaic day 3 embryos per patient based on PGS analysis.
Study Period
2008-10 → 2011-01
NCT01428089
UNKNOWNPhase In=40

Suppression of Daytime and Nighttime Luteinizing Hormone Frequency by Progesterone

During childhood, the levels of certain hormones: gonadotropin-releasing hormone (GnRH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrogen, and progesterone are very low. However, when puberty starts, GnRH and LH pulses begin to increase, but they initially do so at night only. It is unknown why GnRH and LH pulses increase at night and then decrease during the day (instead of

Study Interventions
Progesterone, Placebo
Primary Endpoints
Average luteinizing hormone (LH) interpulse interval and the total number of LH pulses
Study Period
2011-03-11 → 2024-12
NCT04071574
COMPLETEDPhase I / Phase IIn=200

Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility

The study will describe the effectiveness of ovarian stimulation in correlation with female infertility causes in a Lebanese population: a comparative study using 5 protocols of ovulation induction (treatment with "A" gonadotropins alone, "B" short GnRH agonist, "C" multiple-dose GnRH antagonist, "D" long GnRH agonist and "E" combined protocol of GnRH antagonist and agonist) and the outcomes of IC

Study Interventions
Human Chorionic Gonadotropin (hCG), Gonadotropins, GNRH-A Triptorelin
Primary Endpoints
Ovulation Induction
Study Period
2018-02-01 → 2023-05-05
NCT03209518
COMPLETEDN/An=312

Special Drug Use Surveillance of Leuprorelin for Injection Kit 22.5 mg in "Premenopausal Breast Cancer"

The purpose of this survey is to evaluate the safety in patients with premenopausal breast cancer receiving Leuprorelin in the routine clinical setting.

Study Interventions
Leuprorelin acetate
Primary Endpoints
Percentage of Participants Who Had One or More Adverse Events
Study Period
2016-03-18 → 2018-10-10
NCT04189900
COMPLETEDPhase In=2

Generation of Biological Samples Positive to Triptorelin for Anti-doping Control

Background: Androgens are used for doping purpose because they can increase muscle mass and strength. These drugs are included in the list of prohibited substances of the World Anti-Doping Agency (WADA). The prohibition of its use has given rise to a great variety of strategies of indirect androgenic doping, whose purpose is to produce a sustained increase in endogenous testosterone. Triptorelin

Study Interventions
Triptorelin
Primary Endpoints
Urine concentration of triptorelin; Urine concentration of triptorelin
Study Period
2019-04-26 → 2019-05-15
NCT01715129
COMPLETEDPhase IIIn=126

Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer

Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.

Study Interventions
Triptorelin Pamoate 11.25mg
Primary Endpoints
Percentage of Subjects Demonstrating Castration at Day 29 and Maintaining Castration at Day 183
Study Period
2013-01 → 2013-10
NCT04891731
UNKNOWNN/An=120

Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer

Leuprorelin, a LHRH agonist, acts as a potent inhibitor of gonadotropin secretion and is commonly used for the treatment of hormone-responsive prostate cancer, premenopausal HR+ breast cancer, endometriosis and uterine fibroids. It is currently available in 1M, 3M, 6M for subcutaneous administration. Initially administration would stimulate an increase in LH and FSH, causing a transient increase o

Study Interventions
AI or TAM
Primary Endpoints
the suppression proportion of serum estradiol (E2)
Study Period
2021-05 → 2023-09

All data presented on this page is for laboratory research purposes only. Gonadorelin is referenced here as a research reagent. This page does not constitute medical advice, clinical guidance, or endorsement of any compound for human or animal use. All referenced studies are available via PubMed (PMID: 42011011) and the DOI-linked journal publication. Researchers must consult applicable institutional and regulatory frameworks before conducting any protocols.